Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC

EC approves BMS’ Opdivo and Yervoy combo for HCC treatment

The EC has approved BMS Opdivo in combination with Yervoy as a first-line treatment for adults with unresectable or advanced HCC.

Bristol Myers Squibb Receives European Commission Approval for Opdivo®(nivolumab) plus Yervoy®(ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma - Pipelinereview

Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib PRINCETON, NJ, USA I March 07, 2025 I Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo®(nivolumab) plus Yervoy®(ipilimumab) for the first-line …

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC

Nivolumab plus ipilimumab was approved by the European Commission for first-line, unresectable or advanced HCC.